These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 31014142)

  • 41. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
    Thompson PA; Burger JA
    Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
    Jain P; Keating MJ; Wierda WG; Sivina M; Thompson PA; Ferrajoli A; Estrov Z; Kantarjian H; O'Brien S; Burger JA
    Clin Cancer Res; 2017 May; 23(9):2154-2158. PubMed ID: 27797975
    [No Abstract]   [Full Text] [Related]  

  • 43. Outcomes of front-line ibrutinib treated CLL patients excluded from landmark clinical trial.
    Mato AR; Roeker LE; Allan JN; Pagel JM; Brander DM; Hill BT; Cheson BD; Furman RR; Lamanna N; Tam CS; Handunnetti S; Jacobs R; Lansigan F; Bhavsar E; Barr PM; Shadman M; Skarbnik AP; Goy A; Beach DF; Svoboda J; Pu JJ; Sehgal AR; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Rhodes J; Ujjani CS; Nabhan C
    Am J Hematol; 2018 Nov; 93(11):1394-1401. PubMed ID: 30132965
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients.
    Mato AR; Hill BT; Lamanna N; Barr PM; Ujjani CS; Brander DM; Howlett C; Skarbnik AP; Cheson BD; Zent CS; Pu JJ; Kiselev P; Foon K; Lenhart J; Henick Bachow S; Winter AM; Cruz AL; Claxton DF; Goy A; Daniel C; Isaac K; Kennard KH; Timlin C; Fanning M; Gashonia L; Yacur M; Svoboda J; Schuster SJ; Nabhan C
    Ann Oncol; 2017 May; 28(5):1050-1056. PubMed ID: 28453705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of 230 patients with relapsed/refractory deletion 17p chronic lymphocytic leukaemia treated with ibrutinib from 3 clinical trials.
    Jones J; Mato A; Coutre S; Byrd JC; Furman RR; Hillmen P; Osterborg A; Tam C; Stilgenbauer S; Wierda WG; Heerema NA; Eckert K; Clow F; Zhou C; Chu AD; James DF; O'Brien SM
    Br J Haematol; 2018 Aug; 182(4):504-512. PubMed ID: 29873072
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Long-term outcomes in patients with chronic lymphocytic leukemia treated with ibrutinib: Focus on hypertension and cardiovascular toxicity.
    Gordon MJ; Jones JE; George B; Peterson C; Burger JA; Jain N; Keating M; Wierda WG; Durand JB; Ferrajoli A
    Cancer; 2023 Jul; 129(14):2192-2200. PubMed ID: 37016930
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
    Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
    Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The clinical safety of ibrutinib in chronic lymphocytic leukemia.
    Molica S
    Expert Opin Drug Saf; 2015 Oct; 14(10):1621-9. PubMed ID: 26359217
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study.
    Thompson PA; Lévy V; Tam CS; Al Nawakil C; Goudot FX; Quinquenel A; Ysebaert L; Michallet AS; Dilhuydy MS; Van Den Neste E; Dupuis J; Keating MJ; Meune C; Cymbalista F
    Br J Haematol; 2016 Nov; 175(3):462-466. PubMed ID: 27611233
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ibrutinib dose modifications in the management of CLL.
    Hardy-Abeloos C; Pinotti R; Gabrilove J
    J Hematol Oncol; 2020 Jun; 13(1):66. PubMed ID: 32503582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ibrutinib has some activity in Richter's syndrome.
    Giri S; Hahn A; Yaghmour G; Martin MG
    Blood Cancer J; 2015 Jan; 5(1):e277. PubMed ID: 25635530
    [No Abstract]   [Full Text] [Related]  

  • 53. Hodgkin Lymphoma Transformation of Chronic Lymphocytic Leukemia Under Ibrutinib Therapy: Chance Association or Therapy-related?
    Sachanas S; Pangalis GA; Moschogiannis M; Yiakoumis X; Koulieris E; Tsirkinidis P; Kalpadakis C; Rontogianni D
    Anticancer Res; 2017 Jun; 37(6):3277-3280. PubMed ID: 28551676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ibrutinib-induced polyneuropathy: A case report.
    Cömert P; Albayrak M; Yıldız A; Şahin O; Öztürk HB; Reis Aras M
    J Oncol Pharm Pract; 2020 Sep; 26(6):1501-1504. PubMed ID: 32028841
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound.
    Gustine JN; Meid K; Dubeau T; Severns P; Hunter ZR; Guang Y; Xu L; Treon SP; Castillo JJ
    Am J Hematol; 2018 Aug; 93(4):511-517. PubMed ID: 29280186
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Recurrent Uveitis Related to Ibrutinib for Treatment of Chronic Lymphocytic Leukemia.
    Mehraban Far P; Rullo J; Farmer J; Urton T
    Ocul Immunol Inflamm; 2022 May; 30(4):1005-1008. PubMed ID: 33539715
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
    Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
    J Clin Oncol; 2017 Sep; 35(26):3010-3020. PubMed ID: 28715249
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ibrutinib-based therapy impaired neutrophils microbicidal activity in patients with chronic lymphocytic leukemia during the early phases of treatment.
    Prezzo A; Cavaliere FM; Bilotta C; Pentimalli TM; Iacobini M; Cesini L; Foà R; Mauro FR; Quinti I
    Leuk Res; 2019 Dec; 87():106233. PubMed ID: 31639635
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Duvelisib: a new phosphoinositide-3-kinase inhibitor in chronic lymphocytic leukemia.
    Frustaci AM; Tedeschi A; Deodato M; Zamprogna G; Cairoli R; Montillo M
    Future Oncol; 2019 Jul; 15(19):2227-2239. PubMed ID: 31137964
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Atypical primary cutaneous cryptococcosis during ibrutinib therapy for chronic lymphocytic leukemia.
    Peri AM; Rossio R; Tafuri F; Benzecry V; Grancini A; Reda G; Bandera A; Peyvandi F
    Ann Hematol; 2019 Dec; 98(12):2847-2849. PubMed ID: 31741032
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.